Search Results for: Respiratory

2697 interactions found:

Symbols Name 1 Name 2
Pathways 1
Pathways 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
EP300 and YWHAZ E1A binding protein p300 tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta
  • Regulation of gene expression by Hypoxia-inducible Factor
  • RORA activates gene expression
  • RORA activates gene expression
  • Polo-like kinase mediated events
  • Pre-NOTCH Transcription and Translation
  • Pre-NOTCH Transcription and Translation
  • PPARA activates gene expression
  • Formation of the beta-catenin:TCF transactivating complex
  • Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells
  • NOTCH1 Intracellular Domain Regulates Transcription
  • NOTCH1 Intracellular Domain Regulates Transcription
  • NOTCH2 intracellular domain regulates transcription
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
  • HATs acetylate histones
  • Attenuation phase
  • Transcriptional regulation of white adipocyte differentiation
  • Transcriptional regulation of white adipocyte differentiation
  • SUMOylation of transcription cofactors
  • Circadian Clock
  • Circadian Clock
  • B-WICH complex positively regulates rRNA expression
  • Activation of anterior HOX genes in hindbrain development during early embryogenesis
  • CD209 (DC-SIGN) signaling
  • Metalloprotease DUBs
  • Formation of TC-NER Pre-Incision Complex
  • Transcription-Coupled Nucleotide Excision Repair (TC-NER)
  • Dual incision in TC-NER
  • Gap-filling DNA repair synthesis and ligation in TC-NER
  • TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
  • Regulation of TP53 Activity through Acetylation
  • Regulation of TP53 Activity through Methylation
  • PI5P Regulates TP53 Acetylation
  • Activation of the TFAP2 (AP-2) family of transcription factors
  • RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function
  • RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known
  • RUNX3 regulates NOTCH signaling
  • RUNX3 regulates NOTCH signaling
  • Regulation of RUNX3 expression and activity
  • RUNX3 regulates p14-ARF
  • NOTCH3 Intracellular Domain Regulates Transcription
  • NOTCH3 Intracellular Domain Regulates Transcription
  • NOTCH4 Intracellular Domain Regulates Transcription
  • Estrogen-dependent gene expression
  • NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux
  • NGF-stimulated transcription
  • NGF-stimulated transcription
  • TRAF3-dependent IRF activation pathway
  • TRAF6 mediated IRF7 activation
  • FOXO-mediated transcription of cell death genes
  • Transcriptional regulation of granulopoiesis
  • Transcriptional regulation of granulopoiesis
  • Regulation of FOXO transcriptional activity by acetylation
  • Regulation of FOXO transcriptional activity by acetylation
  • Activation of BAD and translocation to mitochondria
  • Translocation of SLC2A4 (GLUT4) to the plasma membrane
  • Deactivation of the beta-catenin transactivating complex
  • Rap1 signalling
  • GP1b-IX-V activation signalling
  • KSRP (KHSRP) binds and destabilizes mRNA
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • RHO GTPases activate PKNs
  • TP53 Regulates Metabolic Genes
  • Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
  • NOTCH4 Activation and Transmission of Signal to the Nucleus
  • Negative regulation of NOTCH4 signaling
  • Regulation of localization of FOXO transcription factors
  • Phenethyl Isothiocyanate
  • Rubinstein-Taybi syndrome
EPAS1 and NDN endothelial PAS domain protein 1 necdin, MAGE family member
  • Regulation of gene expression by Hypoxia-inducible Factor
  • Cellular response to hypoxia
  • Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha
  • Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha
  • Transcriptional regulation of pluripotent stem cells
  • PTK6 Expression
  • Neddylation
  • Pexophagy
  • Interleukin-4 and Interleukin-13 signaling
  • Congenital polycythemia; Familial erythrocytosis (ECYT)
  • Prader-Willi and Angelman syndromes, including: Angelman syndrome (AS); Prader-Willi syndrome (PWS)
EPB41L1 and YWHAZ erythrocyte membrane protein band 4.1 like 1 tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta
  • Trafficking of AMPA receptors
  • Neurexins and neuroligins
  • Activation of BAD and translocation to mitochondria
  • Translocation of SLC2A4 (GLUT4) to the plasma membrane
  • Deactivation of the beta-catenin transactivating complex
  • Rap1 signalling
  • GP1b-IX-V activation signalling
  • KSRP (KHSRP) binds and destabilizes mRNA
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • RHO GTPases activate PKNs
  • TP53 Regulates Metabolic Genes
  • Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
  • NOTCH4 Activation and Transmission of Signal to the Nucleus
  • Negative regulation of NOTCH4 signaling
  • Regulation of localization of FOXO transcription factors
  • Phenethyl Isothiocyanate
EPB41L2 and YWHAZ erythrocyte membrane protein band 4.1 like 2 tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta
  • Neurexins and neuroligins
  • Activation of BAD and translocation to mitochondria
  • Translocation of SLC2A4 (GLUT4) to the plasma membrane
  • Deactivation of the beta-catenin transactivating complex
  • Rap1 signalling
  • GP1b-IX-V activation signalling
  • KSRP (KHSRP) binds and destabilizes mRNA
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • RHO GTPases activate PKNs
  • TP53 Regulates Metabolic Genes
  • Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
  • NOTCH4 Activation and Transmission of Signal to the Nucleus
  • Negative regulation of NOTCH4 signaling
  • Regulation of localization of FOXO transcription factors
  • Phenethyl Isothiocyanate
EPHA8 and PIK3CG EPH receptor A8 phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma
  • EPH-Ephrin signaling
  • EPH-Ephrin signaling
  • EPHA-mediated growth cone collapse
  • EPHA-mediated growth cone collapse
  • EPH-ephrin mediated repulsion of cells
  • EPH-ephrin mediated repulsion of cells
  • GPVI-mediated activation cascade
  • Synthesis of PIPs at the plasma membrane
  • G beta:gamma signalling through PI3Kgamma
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Staurosporine
  • Myricetin
  • LY-294002
  • Quercetin
  • 5-QUINOXALIN-6-YLMETHYLENE-THIAZOLIDINE-2,4-DIONE
  • XL765
  • 2-((9H-PURIN-6-YLTHIO)METHYL)-5-CHLORO-3-(2-METHOXYPHENYL)QUINAZOLIN-4(3H)-ONE
  • N-(5-(4-CHLORO-3-(2-HYDROXY-ETHYLSULFAMOYL)- PHENYLTHIAZOLE-2-YL)-ACETAMIDE
  • 5,5-dimethyl-2-morpholin-4-yl-5,6-dihydro-1,3-benzothiazol-7(4H)-one
  • 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
  • (5E)-5-[(2,2-DIFLUORO-1,3-BENZODIOXOL-5-YL)METHYLENE]-1,3-THIAZOLIDINE-2,4-DIONE
  • (1S,6BR,9AS,11R,11BR)-9A,11B-DIMETHYL-1-[(METHYLOXY)METHYL]-3,6,9-TRIOXO-1,6,6B,7,8,9,9A,10,11,11B-DECAHYDRO-3H-FURO[4,3,2-DE]INDENO[4,5-H][2]BENZOPYRAN-11-YL ACETATE
  • 1-methyl-3-naphthalen-2-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
EPHB2 and GRIN1 EPH receptor B2 glutamate ionotropic receptor NMDA type subunit 1
  • EPH-Ephrin signaling
  • EPH-Ephrin signaling
  • L1CAM interactions
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • Ephrin signaling
  • Ephrin signaling
  • EPH-ephrin mediated repulsion of cells
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Ras activation upon Ca2+ influx through NMDA receptor
  • RAF/MAP kinase cascade
  • Neurexins and neuroligins
  • Synaptic adhesion-like molecules
  • Assembly and cell surface presentation of NMDA receptors
  • Assembly and cell surface presentation of NMDA receptors
  • Negative regulation of NMDA receptor-mediated neuronal transmission
  • Long-term potentiation
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • Glutamic Acid
  • Atomoxetine
  • Pentobarbital
  • Secobarbital
  • Pethidine
  • Acamprosate
  • Gabapentin
  • Memantine
  • Orphenadrine
  • Phenobarbital
  • Prasterone
  • Dcka, 5,7-Dichlorokynurenic Acid
  • D-Serine
  • Cycloleucine
  • Milnacipran
  • CNS-5161
  • Acetylcysteine
  • Ketobemidone
  • Gavestinel
  • Agmatine
  • Ifenprodil
  • Magnesium acetate tetrahydrate
  • Magnesium carbonate
  • Fluciclovine (18F)
EPHB4 and GRIN1 EPH receptor B4 glutamate ionotropic receptor NMDA type subunit 1
  • EPH-Ephrin signaling
  • EPH-Ephrin signaling
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • Ephrin signaling
  • Ephrin signaling
  • EPH-ephrin mediated repulsion of cells
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Ras activation upon Ca2+ influx through NMDA receptor
  • RAF/MAP kinase cascade
  • Neurexins and neuroligins
  • Synaptic adhesion-like molecules
  • Assembly and cell surface presentation of NMDA receptors
  • Assembly and cell surface presentation of NMDA receptors
  • Negative regulation of NMDA receptor-mediated neuronal transmission
  • Long-term potentiation
  • Dasatinib
  • N-(5-chloro-1,3-benzodioxol-4-yl)-6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-amine
  • N'-(5-CHLORO-1,3-BENZODIOXOL-4-YL)-N-(3,4,5- TRIMETHOXYPHENYL)PYRIMIDINE-2,4-DIAMINE
  • N'-(3-CHLORO-4-METHOXY-PHENYL)-N-(3,4,5-TRIMETHOXYPHENYL)-1,3,5-TRIAZINE-2,4-DIAMINE
  • 3-({4-[(5-chloro-1,3-benzodioxol-4-yl)amino]pyrimidin-2-yl}amino)benzenesulfonamide
  • N'-(5-chloro-1,3-benzodioxol-4-yl)-N-(3-methylsulfonylphenyl)pyrimidine-2,4-diamine
  • N-[3-[[4-[(5-CHLORO-1,3-BENZODIOXOL-4-YL)AMINO]PYRIMIDIN-2-YL]AMINO]PHENYL]METHANESULFONAMIDE
  • N'-(5-CHLORO-1,3-BENZODIOXOL-4-YL)-N-(3-MORPHOLIN-4-YLPHENYL)PYRIMIDINE-2,4-DIAMINE
  • 3-({4-[(5-CHLORO-1,3-BENZODIOXOL-4-YL)AMINO]PYRIMIDIN-2-YL}AMINO)BENZAMIDE
  • Tesevatinib
  • Glutamic Acid
  • Atomoxetine
  • Pentobarbital
  • Secobarbital
  • Pethidine
  • Acamprosate
  • Gabapentin
  • Memantine
  • Orphenadrine
  • Phenobarbital
  • Prasterone
  • Dcka, 5,7-Dichlorokynurenic Acid
  • D-Serine
  • Cycloleucine
  • Milnacipran
  • CNS-5161
  • Acetylcysteine
  • Ketobemidone
  • Gavestinel
  • Agmatine
  • Ifenprodil
  • Magnesium acetate tetrahydrate
  • Magnesium carbonate
  • Fluciclovine (18F)
CLN8 and SELENOK CLN8 transmembrane ER and ERGIC protein selenoprotein K
  • Neuronal ceroid lipofuscinosis, including: Infantile Neuronal Ceroid Lipofuscinosis (INCL)/ Santavuori-Haltia Disease (CLN1); Late-Infantile Neuronal Ceroid Lipofuscinosis (LINCL)/ Jansky-Bielschowsky Disease (CLN2); Juvenile Neuronal Ceroid Lipofuscinosis (JNCL)/Batten Disease/ Spielmeyer-Vogt Disease (CLN3); Adult Neuronal Ceroid Lipofuscinosis (ANCL)/ Kufs Disease (CLN4); LINCL variant (CLN5, CLN6, CLN7, CLN8); Batten Disease variant (CLN9); Congenital NCL (CLN10)
  • Progressive myoclonic epilepsy (PME), including: Lafora disease (LBD); Unverricht-Lundborg disease (ULD); Neuronal ceroid lipofuscinoses (NCL); Type I sialidosis; Action myoclonus-renal failure syndrome (AMRF); Type III Gaucher disease (GD)
ERBB2 and INSR erb-b2 receptor tyrosine kinase 2 insulin receptor
  • Signaling by ERBB2
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PLCG1 events in ERBB2 signaling
  • PIP3 activates AKT signaling
  • GRB7 events in ERBB2 signaling
  • Downregulation of ERBB2:ERBB3 signaling
  • GRB2 events in ERBB2 signaling
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Sema4D induced cell migration and growth-cone collapse
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Downregulation of ERBB2 signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • Constitutive Signaling by Overexpressed ERBB2
  • Drug-mediated inhibition of ERBB2 signaling
  • Signaling by ERBB2 KD Mutants
  • Resistance of ERBB2 KD mutants to trastuzumab
  • Resistance of ERBB2 KD mutants to sapitinib
  • Resistance of ERBB2 KD mutants to tesevatinib
  • Resistance of ERBB2 KD mutants to neratinib
  • Resistance of ERBB2 KD mutants to osimertinib
  • Resistance of ERBB2 KD mutants to afatinib
  • Resistance of ERBB2 KD mutants to AEE788
  • Resistance of ERBB2 KD mutants to lapatinib
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Drug resistance in ERBB2 TMD/JMD mutants
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • IRS activation
  • Signal attenuation
  • Insulin receptor signalling cascade
  • Signaling by Insulin receptor
  • Insulin receptor recycling
  • Trastuzumab
  • Lapatinib
  • IGN311
  • Trastuzumab emtansine
  • Varlitinib
  • Pertuzumab
  • Afatinib
  • Tucatinib
  • Tesevatinib
  • Brigatinib
  • Insulin Human
  • Insulin Lispro
  • Insulin Glargine
  • Insulin Pork
  • Mecasermin
  • Insulin Aspart
  • Insulin Detemir
  • Insulin Glulisine
  • Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate
  • NN344
  • AT1391
  • [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
  • Chromic chloride
  • Insulin Degludec
  • Brigatinib
  • Choriocarcinoma
  • Pancreatic cancer
  • Gastric cancer
  • Bladder cancer
  • Endometrial Cancer
  • Ovarian cancer
  • Cholangiocarcinoma
  • Breast cancer
  • Cervical cancer
  • Rabson-Mendenhall syndrome
  • Leprechaunism ; Donohue syndrome
ERBB2 and FLT4 erb-b2 receptor tyrosine kinase 2 fms related receptor tyrosine kinase 4
  • Signaling by ERBB2
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PLCG1 events in ERBB2 signaling
  • PIP3 activates AKT signaling
  • GRB7 events in ERBB2 signaling
  • Downregulation of ERBB2:ERBB3 signaling
  • GRB2 events in ERBB2 signaling
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Sema4D induced cell migration and growth-cone collapse
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Downregulation of ERBB2 signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • Constitutive Signaling by Overexpressed ERBB2
  • Drug-mediated inhibition of ERBB2 signaling
  • Signaling by ERBB2 KD Mutants
  • Resistance of ERBB2 KD mutants to trastuzumab
  • Resistance of ERBB2 KD mutants to sapitinib
  • Resistance of ERBB2 KD mutants to tesevatinib
  • Resistance of ERBB2 KD mutants to neratinib
  • Resistance of ERBB2 KD mutants to osimertinib
  • Resistance of ERBB2 KD mutants to afatinib
  • Resistance of ERBB2 KD mutants to AEE788
  • Resistance of ERBB2 KD mutants to lapatinib
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Drug resistance in ERBB2 TMD/JMD mutants
  • VEGF binds to VEGFR leading to receptor dimerization
  • NOTCH4 Intracellular Domain Regulates Transcription
  • Trastuzumab
  • Lapatinib
  • IGN311
  • Trastuzumab emtansine
  • Varlitinib
  • Pertuzumab
  • Afatinib
  • Tucatinib
  • Tesevatinib
  • Brigatinib
  • Sorafenib
  • Sunitinib
  • Vatalanib
  • TG-100801
  • ABT-869
  • IMC-1C11
  • Pazopanib
  • Axitinib
  • Regorafenib
  • Lenvatinib
  • Nintedanib
  • Choriocarcinoma
  • Pancreatic cancer
  • Gastric cancer
  • Bladder cancer
  • Endometrial Cancer
  • Ovarian cancer
  • Cholangiocarcinoma
  • Breast cancer
  • Cervical cancer
  • Lymphedemas, including: Lymphedema, hereditary I; Lymphedema-distichiasis syndrome (LD); Hypotrichosis-lymphedema-telangiectasia syndrome (HLTS)
ERBB3 and HCK erb-b2 receptor tyrosine kinase 3 HCK proto-oncogene, Src family tyrosine kinase
  • Nef and signal transduction
  • FCGR activation
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • FLT3 Signaling
  • FCGR3A-mediated IL10 synthesis
  • FCGR3A-mediated phagocytosis
  • 1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
  • Phosphonotyrosine
  • Quercetin
  • Bosutinib
  • Lethal congenital contractural syndrome (LCCS)
  • Type I diabetes mellitus
ERBB4 and DUSP10 erb-b2 receptor tyrosine kinase 4 dual specificity phosphatase 10
  • RAF-independent MAPK1/3 activation
  • Negative regulation of MAPK pathway
  • Afatinib
  • Brigatinib
ESR1 and MYBBP1A estrogen receptor 1 MYB binding protein 1a
  • Nuclear signaling by ERBB4
  • PIP3 activates AKT signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Nuclear Receptor transcription pathway
  • SUMOylation of intracellular receptors
  • Ovarian tumor domain proteases
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • RUNX1 regulates estrogen receptor mediated transcription
  • ESR-mediated signaling
  • RUNX1 regulates transcription of genes involved in WNT signaling
  • Regulation of RUNX2 expression and activity
  • Regulation of RUNX2 expression and activity
  • Extra-nuclear estrogen signaling
  • Estrogen-dependent gene expression
  • B-WICH complex positively regulates rRNA expression
  • Diethylstilbestrol
  • Chlorotrianisene
  • Conjugated estrogens
  • Etonogestrel
  • Desogestrel
  • Levonorgestrel
  • Progesterone
  • Lindane
  • Raloxifene
  • Toremifene
  • Medroxyprogesterone acetate
  • Testosterone
  • Mitotane
  • Estrone
  • Tamoxifen
  • Hexachlorophene
  • Estradiol
  • Ethynodiol diacetate
  • Dobutamine
  • Clomifene
  • Dienestrol
  • Fulvestrant
  • Norgestimate
  • Ethinyl Estradiol
  • Melatonin
  • Trilostane
  • Naloxone
  • Fluoxymesterone
  • Estramustine
  • Mestranol
  • Danazol
  • Oxybenzone
  • Allylestrenol
  • Zinc
  • Genistein
  • Prasterone
  • Benzophenone
  • Equilin
  • Compound 19
  • Resveratrol
  • Compound 18
  • Phthalic Acid
  • Pyrazole
  • Dihydrotestosterone
  • Naringenin
  • Compound 4-D
  • 1-[4-(Octahydro-Pyrido[1,2-a]Pyrazin-2-Yl)-Phenyl]-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol
  • Quercetin
  • Afimoxifene
  • 2-Phenyl-1-[4-(2-Piperidin-1-Yl-Ethoxy)-Phenyl]-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol
  • Estriol
  • Estrone sulfate
  • Quinestrol
  • Phenolphthalein
  • Permethrin
  • Ospemifene
  • AP1081
  • Custirsen
  • NP-50301
  • CHF 4227
  • Lasofoxifene
  • Bazedoxifene
  • Methyltestosterone
  • beta-Naphthoflavone
  • 17-METHYL-17-ALPHA-DIHYDROEQUILENIN
  • 4-(2-amino-1-methyl-1H-imidazo[4,5-b]pyridin-6-yl)phenol
  • [5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE
  • 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-8-METHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
  • 4-[(1S,2S,5S,9R)-5-(HYDROXYMETHYL)-8,9-DIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
  • 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-6,8,9-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
  • (2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-[4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]CHROMAN-6-OL
  • (3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
  • (9ALPHA,13BETA,17BETA)-2-[(1Z)-BUT-1-EN-1-YL]ESTRA-1,3,5(10)-TRIENE-3,17-DIOL
  • (9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL
  • 3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
  • 3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
  • Hexestrol
  • dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate
  • Erteberel
  • N-[(1R)-3-(4-HYDROXYPHENYL)-1-METHYLPROPYL]-2-(2-PHENYL-1H-INDOL-3-YL)ACETAMIDE
  • (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
  • 4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol
  • 4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL
  • DIETHYL (1R,2S,3R,4S)-5,6-BIS(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2,3-DICARBOXYLATE
  • 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine
  • 4-[(1S,2R,5S)-4,4,8-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
  • (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-9-OL
  • RALOXIFENE CORE
  • Tibolone
  • Eugenol
  • Synthetic Conjugated Estrogens, A
  • Synthetic Conjugated Estrogens, B
  • Octocrylene
  • Homosalate
  • Phenyl salicylate
  • Enzacamene
  • Propyl Gallate
  • 2-Methoxy-6-{(E)-[(4-methylphenyl)imino]methyl}phenol
ESR1 and PPARGC1A estrogen receptor 1 PPARG coactivator 1 alpha
  • Nuclear signaling by ERBB4
  • PIP3 activates AKT signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Nuclear Receptor transcription pathway
  • SUMOylation of intracellular receptors
  • Ovarian tumor domain proteases
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • RUNX1 regulates estrogen receptor mediated transcription
  • ESR-mediated signaling
  • RUNX1 regulates transcription of genes involved in WNT signaling
  • Regulation of RUNX2 expression and activity
  • Regulation of RUNX2 expression and activity
  • Extra-nuclear estrogen signaling
  • Estrogen-dependent gene expression
  • PPARA activates gene expression
  • Transcriptional activation of mitochondrial biogenesis
  • Activation of PPARGC1A (PGC-1alpha) by phosphorylation
  • Transcriptional regulation of white adipocyte differentiation
  • Transcriptional regulation of white adipocyte differentiation
  • SUMOylation of transcription cofactors
  • Circadian Clock
  • Circadian Clock
  • Regulation of RUNX2 expression and activity
  • Regulation of RUNX2 expression and activity
  • FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
  • Diethylstilbestrol
  • Chlorotrianisene
  • Conjugated estrogens
  • Etonogestrel
  • Desogestrel
  • Levonorgestrel
  • Progesterone
  • Lindane
  • Raloxifene
  • Toremifene
  • Medroxyprogesterone acetate
  • Testosterone
  • Mitotane
  • Estrone
  • Tamoxifen
  • Hexachlorophene
  • Estradiol
  • Ethynodiol diacetate
  • Dobutamine
  • Clomifene
  • Dienestrol
  • Fulvestrant
  • Norgestimate
  • Ethinyl Estradiol
  • Melatonin
  • Trilostane
  • Naloxone
  • Fluoxymesterone
  • Estramustine
  • Mestranol
  • Danazol
  • Oxybenzone
  • Allylestrenol
  • Zinc
  • Genistein
  • Prasterone
  • Benzophenone
  • Equilin
  • Compound 19
  • Resveratrol
  • Compound 18
  • Phthalic Acid
  • Pyrazole
  • Dihydrotestosterone
  • Naringenin
  • Compound 4-D
  • 1-[4-(Octahydro-Pyrido[1,2-a]Pyrazin-2-Yl)-Phenyl]-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol
  • Quercetin
  • Afimoxifene
  • 2-Phenyl-1-[4-(2-Piperidin-1-Yl-Ethoxy)-Phenyl]-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol
  • Estriol
  • Estrone sulfate
  • Quinestrol
  • Phenolphthalein
  • Permethrin
  • Ospemifene
  • AP1081
  • Custirsen
  • NP-50301
  • CHF 4227
  • Lasofoxifene
  • Bazedoxifene
  • Methyltestosterone
  • beta-Naphthoflavone
  • 17-METHYL-17-ALPHA-DIHYDROEQUILENIN
  • 4-(2-amino-1-methyl-1H-imidazo[4,5-b]pyridin-6-yl)phenol
  • [5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE
  • 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-8-METHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
  • 4-[(1S,2S,5S,9R)-5-(HYDROXYMETHYL)-8,9-DIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
  • 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-6,8,9-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
  • (2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-[4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]CHROMAN-6-OL
  • (3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
  • (9ALPHA,13BETA,17BETA)-2-[(1Z)-BUT-1-EN-1-YL]ESTRA-1,3,5(10)-TRIENE-3,17-DIOL
  • (9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL
  • 3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
  • 3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
  • Hexestrol
  • dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate
  • Erteberel
  • N-[(1R)-3-(4-HYDROXYPHENYL)-1-METHYLPROPYL]-2-(2-PHENYL-1H-INDOL-3-YL)ACETAMIDE
  • (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
  • 4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol
  • 4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL
  • DIETHYL (1R,2S,3R,4S)-5,6-BIS(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2,3-DICARBOXYLATE
  • 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine
  • 4-[(1S,2R,5S)-4,4,8-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
  • (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-9-OL
  • RALOXIFENE CORE
  • Tibolone
  • Eugenol
  • Synthetic Conjugated Estrogens, A
  • Synthetic Conjugated Estrogens, B
  • Octocrylene
  • Homosalate
  • Phenyl salicylate
  • Enzacamene
  • Propyl Gallate
  • 2-Methoxy-6-{(E)-[(4-methylphenyl)imino]methyl}phenol
ESR2 and PPARGC1A estrogen receptor 2 PPARG coactivator 1 alpha
  • PIP3 activates AKT signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Nuclear Receptor transcription pathway
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ESR-mediated signaling
  • Extra-nuclear estrogen signaling
  • PPARA activates gene expression
  • Transcriptional activation of mitochondrial biogenesis
  • Activation of PPARGC1A (PGC-1alpha) by phosphorylation
  • Transcriptional regulation of white adipocyte differentiation
  • Transcriptional regulation of white adipocyte differentiation
  • SUMOylation of transcription cofactors
  • Circadian Clock
  • Circadian Clock
  • Regulation of RUNX2 expression and activity
  • Regulation of RUNX2 expression and activity
  • FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
  • Diethylstilbestrol
  • Raloxifene
  • Estrone
  • Tamoxifen
  • Estradiol
  • Trilostane
  • Estramustine
  • Oxybenzone
  • Genistein
  • Prasterone
  • Benzophenone
  • Phthalic Acid
  • Pyrazole
  • Para-Mercury-Benzenesulfonic Acid
  • Naringenin
  • N-Butyl-11-[(7r,8r,9s,13s,14s,17s)-3,17-Dihydroxy-13-Methyl-7,8,9,11,12,13,14,15,16,17-Decahydro-6h-Cyclopenta[a]Phenanthren-7-Yl]-N-Methylundecanamide
  • 5-Alpha-Androstane-3-Beta,17beta-Diol
  • 4-(2-{[4-{[3-(4-Chlorophenyl)Propyl]Sulfanyl}-6-(1-Piperazinyl)-1,3,5-Triazin-2-Yl]Amino}Ethyl)Phenol
  • Quercetin
  • Afimoxifene
  • Estriol
  • Estrone sulfate
  • MF101
  • CHF 4227
  • Lasofoxifene
  • Bazedoxifene
  • 2-(3-FLUORO-4-HYDROXYPHENYL)-7-VINYL-1,3-BENZOXAZOL-5-OL
  • 3-(3-FLUORO-4-HYDROXYPHENYL)-7-HYDROXY-1-NAPHTHONITRILE
  • [5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE
  • 4-(6-HYDROXY-BENZO[D]ISOXAZOL-3-YL)BENZENE-1,3-DIOL
  • 2-(5-HYDROXY-NAPHTHALEN-1-YL)-1,3-BENZOOXAZOL-6-OL
  • 2-(4-HYDROXY-PHENYL)BENZOFURAN-5-OL
  • (3aS,4R,9bR)-2,2-difluoro-4-(4-hydroxyphenyl)-6-(methoxymethyl)-1,2,3,3a,4,9b-hexahydrocyclopenta[c]chromen-8-ol
  • 1-CHLORO-6-(4-HYDROXYPHENYL)-2-NAPHTHOL
  • 4-(4-HYDROXYPHENYL)-1-NAPHTHALDEHYDE OXIME
  • 5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-CARBONITRILE
  • 3-BROMO-6-HYDROXY-2-(4-HYDROXYPHENYL)-1H-INDEN-1-ONE
  • 3-(6-HYDROXY-NAPHTHALEN-2-YL)-BENZO[D]ISOOXAZOL-6-OL
  • (3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
  • (16ALPHA,17ALPHA)-ESTRA-1,3,5(10)-TRIENE-3,16,17-TRIOL
  • (9aS)-4-bromo-9a-butyl-7-hydroxy-1,2,9,9a-tetrahydro-3H-fluoren-3-one
  • Erteberel
  • (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
  • Eugenol
  • Octocrylene
  • Enzacamene
  • Equol
  • 2-Methoxy-6-{(E)-[(4-methylphenyl)imino]methyl}phenol
ESRRA and PPARGC1A estrogen related receptor alpha PPARG coactivator 1 alpha
  • PPARA activates gene expression
  • Transcriptional activation of mitochondrial biogenesis
  • Transcriptional activation of mitochondrial biogenesis
  • Nuclear Receptor transcription pathway
  • Regulation of RUNX2 expression and activity
  • Regulation of RUNX2 expression and activity
  • PPARA activates gene expression
  • Transcriptional activation of mitochondrial biogenesis
  • Activation of PPARGC1A (PGC-1alpha) by phosphorylation
  • Transcriptional regulation of white adipocyte differentiation
  • Transcriptional regulation of white adipocyte differentiation
  • SUMOylation of transcription cofactors
  • Circadian Clock
  • Circadian Clock
  • Regulation of RUNX2 expression and activity
  • Regulation of RUNX2 expression and activity
  • FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
  • Troglitazone
  • Diethylstilbestrol
  • Genistein
  • Afimoxifene
  • beta-Naphthoflavone
  • 1-CYCLOHEXYL-N-{[1-(4-METHYLPHENYL)-1H-INDOL-3-YL]METHYL}METHANAMINE
  • Flavone
ESRRG and PPARGC1A estrogen related receptor gamma PPARG coactivator 1 alpha
  • Nuclear Receptor transcription pathway
  • PPARA activates gene expression
  • Transcriptional activation of mitochondrial biogenesis
  • Activation of PPARGC1A (PGC-1alpha) by phosphorylation
  • Transcriptional regulation of white adipocyte differentiation
  • Transcriptional regulation of white adipocyte differentiation
  • SUMOylation of transcription cofactors
  • Circadian Clock
  • Circadian Clock
  • Regulation of RUNX2 expression and activity
  • Regulation of RUNX2 expression and activity
  • FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
  • Troglitazone
  • Diethylstilbestrol
  • Tamoxifen
  • Estradiol
  • Cholic Acid
  • Afimoxifene
  • 4-HYDROXY-N'-(4-ISOPROPYLBENZYL)BENZOHYDRAZIDE
  • 4-(1-methyl-1-phenylethyl)phenol
  • 4,4'-PROPANE-2,2-DIYLDIPHENOL
  • 4,4'-cyclohexane-1,1-diyldiphenol
ETS1 and CYBC1 ETS proto-oncogene 1, transcription factor cytochrome b-245 chaperone 1
  • Oncogene Induced Senescence
EWSR1 and ATPAF2 EWS RNA binding protein 1 ATP synthase mitochondrial F1 complex assembly factor 2
  • Ewing's sarcoma
  • Myxoid liposarcoma
  • Clear cell sarcoma of soft tissue
  • Extraskeletal myxoid chondrosarcoma
EXT1 and TRAP1 exostosin glycosyltransferase 1 TNF receptor associated protein 1
  • HS-GAG biosynthesis
  • Defective EXT2 causes exostoses 2
  • Defective EXT1 causes exostoses 1, TRPS2 and CHDS
  • Respiratory electron transport
  • Heparan sulfate proteoglycan gene defects, including: Dyssegmental dysplasia, Silverman-Handmaker type; Schwartz-Jampel syndrome; Simpson-Golabi-Behmel syndrome, type 1; Omodysplasia 1; Multiple exostoses
  • Multiple exostoses

Page 50 out of 135 pages